Medicare GLP-1 Bridge Program: Who Qualifies for $50 Wegovy or Zepbound and How to Enroll
From July 1 2026 through December 31 2027, Medicare is running a “GLP-1 Bridge Program” that lets certain beneficiaries fill Wegovy or Zepbound for a predictable $50 copay each month. This guide shows you exactly who is eligible, how the new prior-authorization form works, and the steps to take with your doctor and Part D plan.
The Medicare GLP-1 Bridge Program is a two-year pilot that caps the monthly out-of-pocket cost for Wegovy or Zepbound at $50 for qualifying beneficiaries who meet strict obesity criteria and complete a new prior-authorization form. Coverage runs from July 1 2026 until December 31 2027, does not count toward your Part D true out-of-pocket (TrOOP) total, and ends automatically when the pilot sunsets or if you lose eligibility. If you have Medicare and a BMI of ≥30 (or ≥27 plus at least one weight-related condition), talking to your prescriber now can ensure you are enrolled before annual plan caps are met.
- The GLP-1 Bridge is a CMS pilot that started July 1 2026 and is scheduled to end December 31 2027 (cms.gov).
- It covers only Wegovy (semaglutide) and Zepbound (tirzepatide) for obesity or overweight with a comorbidity-diabetes prescriptions are excluded.
- Eligible enrollees pay a flat $50 copay per 28-day fill, and the amount is not applied to the Part D TrOOP calculation.
- You must obtain plan-specific prior authorization that verifies BMI and at least 12 weeks of lifestyle counseling before starting the drug.
- Spots are limited: once a Part D plan spends its annual bridge allocation, new enrollments freeze until the next plan year.
The Medicare GLP-1 Bridge Program is a temporary coverage pathway
CMS launched the Bridge as a “proof of concept” to evaluate whether broader obesity-drug coverage reduces long-term Medicare spending. Beginning July 1 2026, participating Part D plans may offer Wegovy or Zepbound to qualified members for a flat $50 monthly copay. The pilot is funded through a dedicated CMS allocation, separate from standard plan premiums or rebates (cms.gov). Once the budget is exhausted, plans must pause new enrollments until the next plan year.
Medicare historically excluded weight-loss drugs. Obesity medicines were carved out of Part D by law in 2006, but mounting evidence that GLP-1 receptor agonists cut cardiovascular events and healthcare costs (Kutz et al., 2023) pushed CMS to test limited coverage.
Eligibility focuses on obesity class and cardiometabolic risk
You must meet all seven criteria below to enroll. The program intentionally mirrors FDA labeling for chronic weight management and adds guardrails to prioritize the highest-risk beneficiaries.
| Eligibility Factor | Requirement |
|---|---|
| Medicare enrollment | Part D coverage in a plan that opted into the pilot |
| Body mass index (BMI) | ≥30 kg/m2 OR ≥27 kg/m2 with ≥1 obesity-related condition (HTN, dyslipidemia, OSA, etc.) |
| Age | 18 years or older (no upper limit) |
| Type 2 diabetes | NOT required; diabetes indication prescriptions are excluded |
| Lifestyle counseling | Documented 12 weeks of diet & exercise counseling in the EHR |
| Prior GLP-1 use | No Wegovy or Zepbound fills in the past 180 days |
| Plan budget status | Bridge funds still available for the plan year |
Tip: Ask your prescriber to note specific ICD-10 codes (e.g., E66.9 for obesity, I10 for hypertension) on the prior-authorization form so the plan can confirm criterion #2 without additional chart requests.
Only Wegovy and Zepbound qualify-Ozempic and Mounjaro do not
The Bridge covers the weight-loss brands that have FDA approval for chronic weight management: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Their diabetes counterparts, Ozempic and Mounjaro, remain excluded because Medicare already covers them under the diabetes indication in Part D or Part B.
Why the distinction? CMS wants real-world weight-management data. Covering the weight-loss SKUs ensures dosing and label indications align with obesity research protocols (Ukhanova et al., 2025).
How to enroll in the Bridge program step by step
Enrollment requires coordination between you, your prescriber, and your Part D plan. Follow these three checkpoints.
Checkpoint 1: Verify your plan participates. Call the member services number on the back of your Part D card and ask, “Does my plan offer the Medicare GLP-1 Bridge Program for 2026?” If not, you can switch plans during the next open enrollment period (Oct 15-Dec 7) for coverage starting January 1.
Checkpoint 2: Complete lifestyle counseling. If you have not logged 12 weeks of structured lifestyle counseling, schedule visits now so progress notes are in your chart before the prior-authorization is submitted.
Checkpoint 3: Have your prescriber submit the special PA form. CMS published a standardized form that every plan must accept (cms.gov). Your doctor should attach:
- Most recent height, weight, and BMI calculation
- ICD-10 codes for obesity and each comorbidity
- Proof of 12 weeks of counseling (visit notes, referral letters, or program certificates)
Average turnaround time is 72 hours, but plans have up to 14 days to respond. If approved, the plan will cue the $50 copay in its system so the pharmacy can adjudicate correctly.
Understanding the $50 copay and what it does (and does not) count toward
The Bridge copay is a flat fee and is not treated like normal Part D cost sharing. It:
- Does not apply to your TrOOP total, so it will not push you through the coverage gap.
- Is the same throughout the deductible, initial coverage, and catastrophic phases.
- Cannot be lowered further with manufacturer savings cards, which are prohibited in federal programs.
Why the carve-out? CMS wants to isolate the fiscal impact of covering GLP-1 weight-loss drugs without affecting the broader Part D benefit design. Early modeling predicts that if adherence stays above 40%, long-term medical savings may offset drug costs within 10 years (Hwang et al., 2025).
| Scenario | Your Monthly Cost |
|---|---|
| Approved for Bridge | $50 (flat) |
| Denied PA, standard Part D tiers | Typically full retail $1300-$1400 until deductible met |
| No coverage, retail pharmacy cash price | $1300-$1400 |
Prior authorization hurdles and how to clear them
Most denials cite missing documentation. Top reasons include no proof of counseling or BMI entered in a progress note but not on the PA form. To avoid delays:
Attach lab data: Recent A1c, lipid panel, or blood pressure logs strengthen the comorbidity claim.
Include a weight-management plan: A sentence stating, “Patient will continue monthly dietitian visits and track calories with MyFitnessPal,” shows sustained engagement.
Appeal quickly: Plans must give you written denial reasons. You have 60 days to appeal, and overturned rates for properly completed forms exceed 70% (prior authorization appeal guide).
Pilot timeline: key dates you should mark now
The Bridge is strictly time-boxed. Even if the program saves money, CMS cannot extend it without new legislation. Missing these windows could mean losing coverage.
| Date | Milestone |
|---|---|
| July 1 2026 | Bridge coverage begins for approved beneficiaries |
| Oct 15: Dec 7 2026 | First open enrollment to switch into a participating plan |
| Jun 30 2027 | Last day to submit new PA before annual funding resets |
| Dec 31 2027 | Bridge program ends; copays revert to plan’s standard tier |
Options if you do not qualify for the Bridge
If you miss the eligibility cutoffs or your plan’s Bridge budget is exhausted, you still have choices-just not under the $50 cap.
Compounded GLP-1 therapy online: Licensed U.S. providers on Rx.com prescribe compounded semaglutide from $99 per month and compounded tirzepatide from $149 per month on a 12-month plan, with the visit and shipping included. Compounded GLP-1s are not FDA-approved and are formulated by 503A pharmacies when your prescriber determines a brand alternative is not suitable.
Manufacturer cash programs: NovoCare and LillyDirect list retail prices around $1300-$1400 per 28-day pen. Payment assistance is limited for Medicare due to federal anti-kickback rules.
Prescription discount card: If you already have a prescription but pay cash, you can compare coupon prices at 60 000+ pharmacies through Rx.com.
Should you apply for the Medicare GLP-1 Bridge?
Check the column that fits your situation:
✅ Proceed with Bridge PA
- BMI ≥30 or ≥27 with hypertension, dyslipidemia, OSA
- Documented lifestyle counseling ≥12 weeks
- Enrolled in a Part D plan that opted into the pilot
- No Wegovy or Zepbound fill in past 6 months
- Ready to follow monthly pharmacist check-ins
🏥 Consider other options
- BMI below eligibility threshold
- Your Part D plan did not adopt the Bridge
- Denied PA twice for missing documentation
- Need immediate start before PA turnaround
- Bridge funds exhausted for the plan year
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following while taking a GLP-1 medication:
- Severe nausea or vomiting: risk of dehydration and electrolyte imbalance
- Persistent severe abdominal pain: could signal pancreatitis
- Signs of gallbladder disease such as right-upper-quadrant pain or jaundice
- Difficulty breathing or swallowing: possible severe allergic reaction
- Rapid heartbeat, dizziness, or fainting: may indicate severe hypotension or dehydration
- Changes in vision: report immediately if you have diabetic retinopathy
- Thoughts of self-harm or depression: call 988 or seek emergency help
Scientific References
- Kutz A, Kim DH, Wexler DJ, et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care. 2023.
- Ukhanova M, Wozny JS, Truong CN, et al. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am J Manag Care. 2025.
- Hwang JH, Laiteerapong N, Huang ES, et al. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity. JAMA Health Forum. 2025.
- Medicare GLP-1 Bridge | CMS. cms.gov.
Frequently Asked Questions
Does the $50 copay count toward my Part D deductible or out-of-pocket maximum?
No. CMS treats the Bridge copay as a separate pilot expenditure, so it is excluded from your deductible, initial coverage threshold, and catastrophic true out-of-pocket (TrOOP) tally.
Can I switch from Ozempic to Wegovy within the Bridge?
Yes, if you meet BMI and counseling requirements and have not filled Wegovy in the past 180 days. Ozempic fills for diabetes do not disqualify you.
What happens after December 31 2027?
Your coverage reverts to your plan’s standard formulary rules. Unless Congress passes a permanent change, you would pay the usual retail or tier-based copay for Wegovy or Zepbound starting January 1 2028.
Will Social Security Extra Help (LIS) lower the $50 copay?
No. The Bridge copay is fixed at $50 regardless of Low-Income Subsidy (LIS) status. LIS can still lower costs for other drugs in your Part D plan.
Can I use a discount card or manufacturer coupon on top of the Bridge?
No. Federal anti-kickback statutes bar the use of manufacturer coupons for Medicare patients, and discount cards cannot be combined with the Bridge copay.
How does CMS verify I completed 12 weeks of lifestyle counseling?
Your provider must submit documentation such as office visit notes, dietitian summaries, or a structured program certificate. Plans can audit records, so accuracy matters.
What if my plan runs out of Bridge funds mid-year?
If you are already enrolled, your $50 copay continues through the calendar year. New applicants must wait for the next plan year’s allocation.
Does the Bridge cover follow-up labs or doctor visits?
No. Only the medication copay is subsidized. Office visits, labs, and monitoring are billed to Part B or your Medigap plan as usual.
